Form 4: KALA BIO Director Sells Over 150K Shares
Insider Transaction Report
KALA BIO, Inc. Director Mark T. Iwicki reported the sale of 154,894 shares of common stock at a weighted average price of $0.81 per share.
Summary
- Mark T. Iwicki, a Director of KALA BIO, Inc., sold 154,894 shares of common stock.
- The transaction occurred on October 23, 2025.
- The shares were sold at a weighted average price of $0.81, with individual transaction prices ranging from $0.78 to $0.85.
- Following the sale, Mr. Iwicki beneficially owns 103,540 shares, which include 103,540 unvested Restricted Stock Units (RSUs).
- The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
Sentiment
Score: 4
Explanation: A director selling a substantial number of shares, even under a 10b5-1 plan, can be viewed with slight caution by the market, though the pre-planned nature mitigates some negative sentiment.
Positives
- The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to immediate market conditions.
- The reporting person remains a beneficial owner of 103,540 shares, including unvested RSUs, maintaining some alignment with shareholder interests.
Negatives
- A director selling a significant number of shares (154,894) could be perceived negatively by investors, potentially signaling a lack of confidence.
- The sale reduces the director's direct ownership in the company.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure of Trading Plan | The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 10/23/2025 | Indicates a pre-planned, orderly sale, which can reduce concerns about opportunistic insider trading. |
Stakeholder Impact
- Shareholders: May view the director's sale of shares as a potential negative signal, although the 10b5-1 plan provides context for a pre-scheduled transaction.
Key Dates
| Date | Description |
|---|---|
| 10/23/2025 | Date of earliest transaction (sale of common stock) |
| 10/24/2025 | Date Form 4 was signed by Attorney-in-Fact |
Recommendation
holdWhile a director's sale of shares can sometimes signal a lack of confidence, this transaction was conducted under a pre-arranged 10b5-1 plan, which suggests it was not based on new, material non-public information. The director still retains a significant number of shares, including unvested RSUs. Without additional financial or operational context from other filings, this single insider transaction does not warrant a change from a 'hold' position, but it should be monitored in conjunction with other insider activity and company performance.
Keywords
KALA BIO, KALA, Mark T Iwicki, Director, Insider Sale, Form 4, Stock Transaction, 10b5-1 Plan, Equity Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.